Individuals with increased baseline serum ApoB showed a greater risk of developing incident CKD during the three-year follow-up in the crude analysis, with a hazard ratio (HR) of 1.50 (95% CI: 1.07-2.11) (P = 0.019). This evidence concerns the gene APOB and chronic kidney disease.